bms-986168
mAbexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02294851)
Timeline
Indications
Mechanism of action
- Microtubule-associated protein tauINHIBITOR
MAPT inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bms-986168
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03658135 | Phase 1 | Sep 12, 2018 | University of California, San Francisco |
| NCT03352557 | Phase 2 | May 3, 2018 | Biogen |
| NCT03068468 | Phase 2 | Apr 24, 2017 | Bristol-Myers Squibb |
| NCT02658916 | Phase 1 | Feb 1, 2016 | Bristol-Myers Squibb, University of California, San Francisco |
| NCT02460094 | Phase 1 | Sep 1, 2015 | Bristol-Myers Squibb, University of California, San Francisco |
| NCT02294851 | Phase 1 | Dec 1, 2014 | Bristol-Myers Squibb |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 4 | 4 | 2 | 2014 |
| University of California, San Francisco | Academic/Hospital | 3 | 1 | 1 | 2015 |
| Biogen | For profit | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1